Lifecore Biomedical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lifecore Biomedical (LFCR).

Price Target Range — 5 Quarters

Analyst Consensus — 3 Analysts

1Buy

2Hold

Consensus RatingBuy# Analysts3Avg. Consensus PT$8Upside to Avg. PT+22.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	Barrington Research	Michael Petusky	Downgrade	Outperform→Market Perform	—
Sep 28, 2026	William Blair	Max Smock	Downgrade	Outperform→Market Perform	—
Jun 16, 2026	Barrington Research	Michael Petusky	PT Raise	Outperform	$6→$7
Apr 29, 2026	Barrington Research	Michael Petusky	PT Raise	Outperform	$6→$6
Mar 27, 2026	Barrington Research	Michael Petusky	Maintained	Outperform	$6
Mar 24, 2026	Barrington Research	Michael Petusky	Maintained	Outperform	$6
Mar 17, 2026	Barrington Research	Michael Petusky	Upgrade	Market Perform→Outperform	$6
Sep 4, 2025	Keybanc	Paul Knight	Initiate	Sector Weight	—
May 21, 2025	William Blair	Max Smock	Initiate	Outperform	—
Jan 3, 2025	Stephens & Co.	Jacob Johnson	Maintained	Equal-Weight	$6
Nov 22, 2024	Craig-Hallum	Matthew Hewitt	PT Raise	Buy	$8→$10
Oct 7, 2024	Stephens & Co.	Jacob Johnson	PT Raise	Equal-Weight	$5→$6
Sep 5, 2024	Craig-Hallum	Matthew Hewitt	Initiate	Buy	$8
Aug 28, 2024	Barrington Research	Michael Petusky	Downgrade	Outperform→Market Perform	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barrington Research Downgrades Lifecore Biomedical to Market Perform

Barrington Research analyst Michael Petusky downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.

Benzinga Newsdesk

PRO
William Blair Downgrades Lifecore Biomedical to Market Perform

William Blair analyst Max Smock downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $6 to $6.5.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $5.5 to $6.

Benzinga Newsdesk

PRO
Barrington Research Upgrades Lifecore Biomedical to Outperform, Announces $5.5 Price Target

Barrington Research analyst Michael Petusky upgrades Lifecore Biomedical (NASDAQ:LFCR) from Market Perform to Outperform and announces $5.5 price target.

Benzinga Newsdesk

Lifecore Stock Sinks As Delayed Launches Push Growth Further Out

Lifecore stock plunges after earnings miss and weak 2026 outlook, with customer losses and delayed growth plans weighing on shares.

Vandana Singh

Lifecore Biomedical Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Lifecore Biomedical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barrington Research Downgrades Lifecore Biomedical to Market Perform

PRO
William Blair Downgrades Lifecore Biomedical to Market Perform

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6

PRO
Barrington Research Upgrades Lifecore Biomedical to Outperform, Announces $5.5 Price Target

Lifecore Stock Sinks As Delayed Launches Push Growth Further Out

People Also Watch

People Also Watch

Lifecore Biomedical Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Lifecore Biomedical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarrington Research Downgrades Lifecore Biomedical to Market Perform

PROWilliam Blair Downgrades Lifecore Biomedical to Market Perform

PROBarrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

PROBarrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6

PROBarrington Research Upgrades Lifecore Biomedical to Outperform, Announces $5.5 Price Target

Lifecore Stock Sinks As Delayed Launches Push Growth Further Out

People Also Watch

People Also Watch

PRO
Barrington Research Downgrades Lifecore Biomedical to Market Perform

PRO
William Blair Downgrades Lifecore Biomedical to Market Perform

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6

PRO
Barrington Research Upgrades Lifecore Biomedical to Outperform, Announces $5.5 Price Target